سعر فاتروكسيم 550مجم 10 اقراص 2025

Rifaximin 550 mg oral film-coated tablets (ATM / EGPI), pack of 10.

• Reduction in risk of overt hepatic encephalopathy recurrence in adults.DailyMed (U.S. NLM)
• Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.DailyMed (U.S. NLM)

• Most common in the HE trial (550 mg twice daily, 10% or more): peripheral oedema, nausea, constipation, dizziness, fatigue, urinary tract infection, insomnia, anaemia, pruritus and ascites. IBS-D (2% or more): ALT increased, nausea. Post-marketing: hypersensitivity incl. exfoliative dermatitis, angioedema and anaphylaxis; C. difficile colitis; SJS/TEN; rhabdomyolysis in patients with cirrhosis.International label, same formulation · DailyMed (U.S. NLM)

• Hypersensitivity to rifaximin, any rifamycin antimicrobial agent or any component (reactions have included exfoliative dermatitis, angioneurotic oedema and anaphylaxis).International label, same formulation · DailyMed (U.S. NLM)

• Severe (Child-Pugh C) hepatic impairment: increased systemic exposure; exercise caution.International label, same formulation · DailyMed (U.S. NLM)
• Clostridioides difficile-associated diarrhoea has been reported and may range from mild diarrhoea to fatal colitis; consider CDAD in any patient with diarrhoea after antibiotic use.International label, same formulation · DailyMed (U.S. NLM)
• Use only for proven or strongly suspected bacterial infection to reduce development of drug-resistant bacteria.International label, same formulation · DailyMed (U.S. NLM)

• P-glycoprotein inhibitors (cyclosporine)Cyclosporine significantly increased systemic rifaximin exposure; caution, especially with hepatic impairment.DailyMed (U.S. NLM)
• WarfarinChanges in INR reported post-marketing; monitor INR and prothrombin time and adjust warfarin if needed.DailyMed (U.S. NLM)

• No human data to inform drug-associated risk; teratogenic effects (ocular, oral/maxillofacial, cardiac and lumbar spine malformations) were seen in rats and rabbits. Advise pregnant women of the potential risk to a fetus.International label, same formulation · DailyMed (U.S. NLM)
• No information on presence in human milk or effects on the breastfed infant; weigh benefits of breastfeeding against the mother's need and potential infant effects.International label, same formulation · DailyMed (U.S. NLM)

• Rifaximin: Binds the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis; minimal systemic absorption after oral dosing.